Adicet Bio, Inc. (ACET)
Company Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.
The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.
Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.
The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands.
Adicet Bio, Inc. is based in Boston, Massachusetts.
| Country | United States |
| Founded | 1947 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 132 |
| CEO | Chen Schor BA, CPA, M.B.A. |
Contact Details
Address: 4 Tri Harbor Court Port Washington, New York 11050 United States | |
| Phone | (516) 627-6000 |
| Website | adicetbio.com |
Stock Details
| Ticker Symbol | ACET |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000002034 |
| CUSIP Number | 007002108 |
| ISIN Number | US0070021086 |
| Employer ID | 11-1720520 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Chen Schor BA, CPA, CPA, M.B.A., MBA | Chief Executive Officer, President and Director |
| Dr. Aya Jakobovits Ph.D. | Founder and Independent Director |
| Brian Nicholas Harvey | Chief Financial Officer |
| Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer and Senior Vice President |
| Dr. Donald Healey | Chief Technology Officer |
| Dr. Blake Aftab Ph.D. | Senior Vice President and Chief Scientific Officer |
| Amy Locke | Head of Human Resources |
| Dr. Nancy L. Boman M.D., Ph.D. | Senior Vice President and Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 1, 2019 | 15-12G | Securities registration termination |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | 8-K | Current Report |
| Sep 20, 2019 | 8-K | Current Report |
| Aug 26, 2019 | 8-K | Current Report |